Immunomedics

Immunomedics
Immunomedics
Type	Public
Traded as	Nasdaq: IMMU
Industry	Biotechnology
Founded	July 1982; 44 years ago
Founder	David M. Goldenberg
Defunct	October 23, 2020; 6 years ago
Headquarters	Morris Plains, New Jersey
Parent	Gilead Sciences
Website	www.immunomedics.com

Immunomedics was a biotechnology company focused on the development of antibody-drug conjugates for the treatment of cancer. In 2020, the company was acquired by Gilead Sciences for $21 billion.

History

Immunomedics was founded in July 1982 by David M. Goldenberg.

Michael Pehl was named CEO in December 2017 but left for personal reasons in February 2019. At that time, Dr. Behzad Aghazadeh was named Executive Chairman.

In October 2020, Gilead Sciences acquired the company. In March 2022, Gilead announced the closing of the former Immunomedics facility in Morris Plains.

Products

Epratuzumab is a humanized anti-CD22 monoclonal antibody in phase III trials for pediatric leukemia.^{[citation needed]}
Sacituzumab govitecan (IMMU-132 / Trodelvy) is an anti-Trop-2-SN-38 antibody-drug conjugate for breast cancer and solid tumors. It was approved in April 2020 by the FDA for the treatment of adult patients with metastatic triple-negative breast cancer (mTNBC) who have received at least two prior therapies for patients with relapsed or refractory metastatic disease. In 2017, the company scrapped a licensing deal for the drug with Seagen that led to the resignation of founder David M. Goldenberg.
Labetuzumab (IMMU-130) is an anti-CEACAM5-SN-38 antibody-drug conjugate in clinical trials for colorectal cancer.^{[citation needed]}
Veltuzumab is an anti-CD20 monoclonal antibody for treatment of cancer.^{[citation needed]}
Milatuzumab (IMMU-110) is an anti-CD74 monoclonal antibody for autoimmune diseases.^{[citation needed]}
IMMU-114 is an anti-HLA-DR for hematological cancers.

References

1 2 "Gilead Sciences Completes Acquisition of Immunomedics, Inc" (Press release). Business Wire. October 23, 2020.
↑ Feuerstein, Adam (January 25, 2017). "Immunomedics Sale Hinges on Proxy Battle Over Fate of Controversial Founder". TheStreet.com.
↑ Vinluan, Frank (February 28, 2019). "Immunomedics CEO Michael Pehl Resigns". Xconomy.
↑ "Immunomedics Form 8-K". U.S. Securities and Exchange Commission. February 22, 2019.
↑ "Gilead Sciences will lay off 114 staffers based out of former Immunomedics headquarters". 8 March 2022.
↑ "FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments" (Press release). Food and Drug Administration. April 22, 2020. Archived from the original on April 23, 2020.
↑ LEE, ARMIE MARGARET (May 5, 2017). "Immunomedics, Seattle Genetics Scrap License Deal". TheStreet.com.
↑ Chen, X; Chang, C-H; Stein, R; Goldenberg, D M (October 24, 2011). "The humanized anti-HLA-DR moAb, IMMU-114, depletes APCs and reduces alloreactive T cells: implications for preventing GVHD". Nature. 47 (7): 967–980. doi:10.1038/bmt.2011.203. PMID 22020022. S2CID 8988947.

[gilead-1] 1 2 "Gilead Sciences Completes Acquisition of Immunomedics, Inc" (Press release). Business Wire. October 23, 2020.

[2] Feuerstein, Adam (January 25, 2017). "Immunomedics Sale Hinges on Proxy Battle Over Fate of Controversial Founder". TheStreet.com.

[3] Vinluan, Frank (February 28, 2019). "Immunomedics CEO Michael Pehl Resigns". Xconomy.

[4] "Immunomedics Form 8-K". U.S. Securities and Exchange Commission. February 22, 2019.

[5] "Gilead Sciences will lay off 114 staffers based out of former Immunomedics headquarters". 8 March 2022.

[6] "FDA Approves New Therapy for Triple Negative Breast Cancer That Has Spread, Not Responded to Other Treatments" (Press release). Food and Drug Administration. April 22, 2020. Archived from the original on April 23, 2020.

[7] LEE, ARMIE MARGARET (May 5, 2017). "Immunomedics, Seattle Genetics Scrap License Deal". TheStreet.com.

[8] Chen, X; Chang, C-H; Stein, R; Goldenberg, D M (October 24, 2011). "The humanized anti-HLA-DR moAb, IMMU-114, depletes APCs and reduces alloreactive T cells: implications for preventing GVHD". Nature. 47 (7): 967–980. doi:10.1038/bmt.2011.203. PMID 22020022. S2CID 8988947.